Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Black Diamond Therapeutics slashes workforce by 30% while discontinuing development of BDTX-189

By Brian Buntz | April 26, 2022

Black Diamond Therapeutics

Precision oncology firm Black Diamond Therapeutics (Nasdaq:BDTX) has announced a restructuring plan to free up cash to prioritize the development of BDTX-1535 and BDTX-4933.

The company plans on trimming nearly one-third of its workforce.

BDTX shares ticked up about 1% to $2.75 after announcing the news yesterday but fell 4% today to $2.64.

According to the company, the reorganization could provide sufficient cash runway to last until the third quarter of 2024.

“In order to increase our operational efficiency and execute on our mission, we have made the difficult decision to reduce our workforce by approximately 30%,” said David Epstein, Black Diamond Therapeutics CEO, in a press release.

The company is also halting development work on BDTX-189. This drug candidate would have potentially been indicated for advanced breast cancer, biliary cancer, male breast cancer, non-small cell lung cancer, ovarian cancer and solid tumors.

BDTX-189 is an orally available, irreversible small molecule inhibitor.

When announcing its Q4 results in mid-March, Black Diamond Therapeutics said it anticipated announcing further guidance related to the program in 2022.

Black Diamond will continue to enroll subjects in the safety expansion cohort of the Phase 1 study associated with BDTX-189 but halt the development of the broader program, given changes in the competitive landscape.

BDTX-1535 is now the subject of a Phase 1 study.

In March, Black Diamond ​​said it would initiate IND-enabling studies for BDTX-4933 in the first quarter of the year.

.


Filed Under: clinical trials, Drug Discovery, Oncology
Tagged With: BDTX-1535, BDTX-189, BDTX-4933, Black Diamond Therapeutics, oncology
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE